Health state utilities for relapsed or refractory large B-cell lymphoma treatments: a time trade-off study in the Japanese general population

This study provides early economic insights, based on general population preferences, suggesting that epcoritamab's subcutaneous injection and outpatient administration beyond Cycle 2 may be associated with improved QOL compared to other therapies, regardless of efficacy and safety.